Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
Investors may be wondering whether Arcutis Biotherapeutics at around US$23.27 still offers value, or if most of the upside is already reflected in the price. The stock has delivered a 75.1% return over the past year, even though it is down 19.8% year to date, highlighting recent weakness compared with a much stronger one-year picture. Recent headlines have focused on Arcutis Biotherapeutics as a higher risk, higher reward biotech name, with attention on its clinical pipeline and funding position as key drivers of sentiment. This backdrop helps explain why the share price has been strong over the past 12 months despite shorter term pullbacks. On Simply Wall St's valuation checks, Arcutis Biotherapeutics currently holds a 6 out of 6 value score . The sections that follow compare traditional valuation methods with a broader way of thinking about what the stock might be worth over time. Arcutis Biotherapeutics delivered 75.1% returns over the last year. See how this stacks up to
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026GlobeNewswire
- Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive [Yahoo! Finance]Yahoo! Finance
- How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets [Yahoo! Finance]Yahoo! Finance
- Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Arcutis Biotherapeutics (ARQT) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ARQT
Earnings
- 2/25/26 - Beat
ARQT
Sec Filings
- 4/3/26 - Form 4
- 4/1/26 - Form 144
- 3/26/26 - Form SCHEDULE
- ARQT's page on the SEC website